Ragaglitazar

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameRagaglitazar
Drug Alias NameRagaglitazarum拉格列扎DRF-2725NNC-61-0029(-)-DRF-2725 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonistsPeroxisome proliferator-activated receptor α agonists
TargetsPeroxisome proliferator-activated receptor γPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovo Nordisk A/S
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A